Pulmocide pulls in $92m

May 27, 2021 • Thierry Heles

Asahi Kasei, GlaxoSmithKline and Johnson & Johnson helped the respiratory disease drug developer boost its overall funding to $150m.

Pulmocide, a UK-based developer of therapies for serious acute and chronic respiratory diseases, secured $92m in series C commitments today from investors including pharmaceutical firms Asahi Kasei, GlaxoSmithKline and Johnson & Johnson.

Investment company Jeito Capital led the oversubscribed round, which also attracted F-Prime Capital, a subsidiary of investment and financial services group Fidelity, as well as IP Group, Adjuvant Capital, SV Health Investors and Longwood Fund.

GlaxoSmithKline and Johnson & Johnson invested through SR One and Johnson & Johnson…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.

Find out more

FUNDING ROUND DATA

Which corporates are backing which startups? Search our corporate deal database.

CVC DIRECTORY

Find details about global CVC units in the CVC Directory

NOMINATE

Make a nomination for Rising Stars and Emerging Leaders

About us

GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.